**Chapter 9**

[117] Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005;**2**(1):3-14

*Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications*

[118] Ha SW, Hwang K, Jin J, Cho AS, Kim TY, Hwang SI, et al. Ultrasoundsensitizing nanoparticle complex for overcoming the blood-brain barrier: An effective drug delivery system. International Journal of Nanomedicine.

2019;**14**:3743-3752

[119] Sugiyama S, Yamashita Y, Kikuchi T, Sonoda Y, Kumabe T, Tominaga T. Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation

or systemic administration of temozolomide in intracranial brain tumor xenografts. Neurological Research. 2008;**30**(9):960-967

[120] Tosi U, Souweidane MM.

[122] Hoshino T, Wilson CB, Rosenblum ML, Barker M.

1975;**43**(2):127-135

**129**(2–3):97-103

**160**

Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. Journal of Neurosurgery.

[123] Chou FH, Tsai KY, Su CY, Lee CC. The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year followup study. Schizophrenia Research. 2011;

2020;**137**:38-42

1396-1401

Longitudinal monitoring of Gd-DTPA following convection enhanced delivery in the brainstem. World Neurosurgery.

[121] Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;**344**(6190):
